Cargando…

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

BACKGROUND: Despite the incorporation of novel therapeutics, advanced triple negative breast cancer (TNBC) still represents a relevant clinical problem. Considering this, as well as the clinical efficacy of antibody-drug conjugates (ADCs), we aimed at identifying novel ADC targets that could be used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montero, Juan Carlos, Calvo-Jiménez, Elisa, del Carmen, Sofía, Abad, Mar, Ocaña, Alberto, Pandiella, Atanasio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941813/ https://www.ncbi.nlm.nih.gov/pubmed/35317825 http://dx.doi.org/10.1186/s13046-022-02330-4

Ejemplares similares

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
por: Pandiella, Atanasio, et al.
Publicado: (2015)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2022)

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
por: Cuenca-López, María D, et al.
Publicado: (2014)

An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
por: Montero, Juan Carlos, et al.
Publicado: (2023)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
por: Montero, Juan Carlos, et al.
Publicado: (2009)

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
por: Juan, Alberto, et al.
Publicado: (2020)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
por: Juan, Alberto, et al.
Publicado: (2020)

Conditional deletion of CD98hc inhibits osteoclast development
por: Tsumura, Hideki, et al.
Publicado: (2015)

CD98hc is a target for brain delivery of biotherapeutics
por: Chew, Kylie S., et al.
Publicado: (2023)

Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers
por: Morafraile, Esther Cabañas, et al.
Publicado: (2023)

Personalized therapies in the cancer "omics" era
por: Ocaña, Alberto, et al.
Publicado: (2010)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

The in silico human surfaceome
por: Bausch-Fluck, Damaris, et al.
Publicado: (2018)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Therapeutic potential of ERK5 targeting in triple negative breast cancer
por: Ortiz-Ruiz, María Jesús, et al.
Publicado: (2014)

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers
por: Perez-Peña, Javier, et al.
Publicado: (2017)

Extracellular domain of CD98hc is required for early murine development
por: Sato, Yukiyasu, et al.
Publicado: (2011)

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
por: Morcillo-Garcia, Sara, et al.
Publicado: (2019)

Dynamic profiling of medulloblastoma surfaceome
por: Bakhshinyan, David, et al.
Publicado: (2023)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

CD98hc facilitates B cell proliferation and adaptive humoral immunity
por: Cantor, Joseph, et al.
Publicado: (2009)

Author Correction: CD98hc is a target for brain delivery of biotherapeutics
por: Chew, Kylie S., et al.
Publicado: (2023)

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
por: Orive‐Ramos, Ana, et al.
Publicado: (2017)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2)
por: Fogelstrand, Per, et al.
Publicado: (2009)

Considerations for the clinical development of immuno-oncology agents in cancer
por: Pandiella, Atanasio, et al.
Publicado: (2023)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Breast Cancer Heterogeneity and Response to Novel Therapeutics
por: Baliu-Piqué, Mariona, et al.
Publicado: (2020)

HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bi75k2bpur90jejhr4hhc0tqrj